Month: April 2019

Check out the companies making headlines after the bell: Shares of Amazon initially jumped 2% in extended trading Thursday before giving up those gains following the release of the e-commerce giant’s strong first-quarter earnings. Jeff Bezos’ company reported earnings per share of $7.09 on revenue of $59.70 billion. Wall Street expected earnings per share of
0 Comments
The Time Warner acquisition made AT&T (NYSE:T) less of a phone company than Verizon Communications (NYSE:VZ) and more of an entertainment company. That is not its big problem. Source: Shutterstock This week, AT&T reported earnings of $4.1 billion, 56 cents per fully diluted share, on revenues of $44.8 billion. This included results from what AT&T
0 Comments
U.S. stock futures are trading mixed this morning. Strong earnings reports out of the tech sector are buoying the Nasdaq-100 while dismal releases from industrials are weighing on the Dow Jones Industrial Average. Ahead of the bell, futures on the Dow Jones Industrial Average are down 0.26%, and S&P 500 futures are higher by 0.12%.
0 Comments
Check out the companies making headlines midday Wednesday: Domino’s Pizza — Shares of Domino’s Pizza surged 8.9% on stronger-than-forecast quarterly earnings. The company reported earnings of $2.20, 11 cents higher than a Refinitiv estimate. Anadarko Petroleum — The energy company’s stock jumped 12% after Occidental Petroleum announced a bid of $76 a share for Anadarko,
0 Comments
Major U.S. indices are mostly flat on Wednesday, digesting the big rally they had on Tuesday. Since we remain in the thick of earnings season though, we’re seeing big moves in individual stocks too. Thursday will be busy with Tesla (NASDAQ:TSLA), Microsoft (NASDAQ:MSFT) and Facebook (NASDAQ:FB) all reporting on Wednesday after the closer. Let’s look
0 Comments
The collapse of healthcare stocks, especially drug companies, may have finally abated. Merck (NYSE:MRK) has fallen 12% from its April 3 high. But the MRK freefall seems to have finally leveled off. Source: Shutterstock The instinctive reaction would be to buy the dip. Merck’s five-year gain is now half that of the average S&P 500
0 Comments